Viatris
VTRS
502 hedge funds and large institutions have $11.8B invested in Viatris in 2018 Q4 according to their latest regulatory filings, with 87 funds opening new positions, 161 increasing their positions, 187 reducing their positions, and 88 closing their positions.
0% more call options, than puts
Call options by funds: $166M | Put options by funds: $166M
0.05% less ownership
Funds ownership: 83.77% → 83.72% (-0.05%)
1% less first-time investments, than exits
New positions opened: 87 | Existing positions closed: 88
2% less funds holding
Funds holding: 511 → 502 (-9)
14% less repeat investments, than reductions
Existing positions increased: 161 | Existing positions reduced: 187
24% less funds holding in top 10
Funds holding in top 10: 17 → 13 (-4)
26% less capital invested
Capital invested by funds: $15.8B → $11.8B (-$4.05B)
Top Buyers
| 1 |
Goldman Sachs
New York
|
+$126M |
| 2 |
Wellington Management Group
Boston,
Massachusetts
|
+$105M |
| 3 |
D.E. Shaw & Co
New York
|
+$95.6M |
| 4 |
AQR Capital Management
Greenwich,
Connecticut
|
+$94.5M |
| 5 |
Arrowstreet Capital
Boston,
Massachusetts
|
+$49.4M |
Top Sellers
VTRS Hedge Fund Activity: Q4 2018 in Review
502 of the 4,488 institutional investors tracked by Wall St. Rank reported a position in Viatris (VTRS) for Q4 2018, worth a combined $11.8B — down 26% from $15.8B a quarter earlier.
Sellers outnumbered buyers: 88 funds closed out of VTRS and 87 opened new positions — a net loss of 1 holder — while 187 trimmed existing stakes and 161 added.
The largest buyer was Goldman Sachs, adding an estimated $126M. The largest seller was PFM Health Sciences, exiting entirely with an estimated $172M sold.
- 502 institutional investors held Viatris (VTRS) as of Q4 2018, down from 511 in Q3 2018.
- Funds reported $11.8B of Viatris stock for Q4 2018, down 26% quarter-over-quarter.
- 87 funds opened new Viatris positions in Q4 2018 and 88 closed out, a net change of -1 holder.
- The largest Viatris buyer in Q4 2018 was Goldman Sachs, an estimated $126M added.
- The largest Viatris seller in Q4 2018 was PFM Health Sciences, an estimated $172M sold.
Based on aggregated 13F filings for Q4 2018.